Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2804)	5/3/2010 10:34:06 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

RPTP is still up 34.69% with volume of > 636Ks already > 7x its ADV bigcharts.marketwatch.com It announced positive PIIa results from its study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, which is believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans. Patients showed a marked decline in ALT levels during the treatment period with 7 of 11 patients achieving a greater than 50% reduction and 6 of 11 reduced to within normal range. AST levels also showed significant improvements with patients averaging 41% reduction by the end of the treatment. The reduction in liver enzymes was largely sustained during the 6 month post-treatment monitoring phase. Other important liver function markers showed positive trends. Levels of cytokeratin 18 decreased by an average of 45%. Adiponectin levels increased by an average of 35% during the treatment period. (Reduced adiponectin levels are thought to be a marker of the pathogenesis and progression of NASH.) Delayed-release cysteamine bitartrate demonstrated a strong, favorable safety profile, with mean gastrointestinal symptom scores of 1.1 at baseline and 0.7 after 6 months of treatment. Apparently there is now changes from the plans of last year of liquidating the company and distributing its assets.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2804)	5/6/2010 9:38:38 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

AEZS is up 16.33% in pre-market. Volume is already above 1M, but still below its ADV.<g> bigcharts.marketwatch.com It announced that it has received orphan-drug designation for its AEZS-108 for the treatment of ovarian Ca. The drug is currently in a PII for advanced ovarian and advanced endometrial Cas in Europe. AEZS expects to report results of that PII later this Yr. The 1stQ results are scheduled to be released before the market opens on Thursday, May 13. They wil held a CC and webcast to discuss these results later that same day at 2:30 PM. As previously mentioned, with some good news the stock could retest its Apr14 H at $1.82 which is above the ACTAY of $1.42 And if it could retest the June2009 H at $3.29 it would be a good % gain from present levels.<g> bigcharts.marketwatch.com Bernard